The move marks an important step in Ipsen’s growth journey in the Nordics and reflects the company’s ambition to move closer to one of Europe’s most advanced life science ecosystems, it states. It also aims to strengthen collaboration in research, healthcare, and innovation.

“Moving to Hagastaden brings us closer to leading research institutions, clinical expertise, and key partners. It creates new opportunities for collaboration and strengthens our ability to develop treatments that make a difference for patients. For us, this is about more than a new workplace; it is about becoming part of an environment where ideas are shared, partnerships are built, and innovation can flourish,” says Julien Dagher, General Manager Nordics & Baltics at Ipsen.

Through the move, Ipsen says it is strengthening its long-term commitment to the Nordics and its role in shaping the future life science sector in the region.